Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study
European Heart Journal · 2024
DOI: 10.1093/eurheartj/ehad659 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal, 2024. Verfasst von Mariam Anjum und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway. Hauptthemen laut MEDLINE: Stroke, Atrial Fibrillation, Brain Ischemia, Ischemic Stroke. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Norwegian South-East Regional Health Authority.
Themen: Schlaganfall
Abstract (Originalsprache)
Background and Aims The benefit of oral anticoagulant (OAC) therapy in atrial fibrillation (AF) and intermediate stroke risk is debated. In a nationwide Norwegian cohort with a non-sex CHA2DS2-VASc risk score of one, this study aimed to investigate (i) stroke and bleeding risk in AF patients with and without OAC treatment, and (ii) the risk of stroke in non-anticoagulated individuals with and without AF.
Methods
A total of 1 118 762 individuals including 34 460 AF patients were followed during 2011–18 until ischaemic stroke, intracranial haemorrhage, increased CHA2DS2-VASc score, or study end. One-year incidence rates (IRs) were calculated as events per 100 person-years (%/py). Cox regression models provided adjusted hazard ratios (aHRs [95% confidence intervals]).
Results
Among AF patients, the ischaemic stroke IR was 0.51%/py in OAC users and 1.05%/py in non-users (aHR 0.47 [0.37–0.59]). Intracranial haemorrhage IR was 0.28%/py in OAC users and 0.19%/py in non-users (aHR 1.23 [0.88–1.72]). Oral anticoagulant use was associated with an increased risk of major bleeding (aHR 1.37 [1.16–1.63]) but lower risk of the combined outcome of ischaemic stroke, major bleeding, and mortality (aHR 0.57 [0.51–0.63]). Non-anticoagulated individuals with AF had higher risk of ischaemic stroke compared to non-AF individuals with the same risk profile (aHR 2.47 [2.17–2.81]).
Conclusions
In AF patients at intermediate risk of stroke, OAC use was associated with overall favourable clinical outcomes. Non-anticoagulated AF patients had higher risk of ischaemic stroke compared to the general population without AF with the same risk profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.
- Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
- Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.
- Department of Internal Medicine, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.
- Stroke Unit, Department of Internal Medicine, St.Olavs Hospital, Norway.
- Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Science, Norwegian University of Science and Technology, Norway.
ORCID-Profile: Mariam Anjum, Inger Ariansen, Arnljot Tveit, Trygve Berge
Förderung
- Norwegian South-East Regional Health Authority
Zitieren
APA
Anjum, M., Ariansen, I., Hjellvik, V., Selmer, R., Kjerpeseth, L. J., Skovlund, E., Myrstad, M., Ellekjær, H., Christophersen, I. E., Tveit, A., & Berge, T. (2024). Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehad659
Vancouver
Anjum M, Ariansen I, Hjellvik V, Selmer R, Kjerpeseth LJ, Skovlund E, et al. Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study. European Heart Journal. 2024. doi:10.1093/eurheartj/ehad659
BibTeX
@article{Anjum2024,
author = {Anjum, Mariam and Ariansen, Inger and Hjellvik, Vidar and Selmer, Randi and Kjerpeseth, Lars J and Skovlund, Eva and Myrstad, Marius and Ellekjær, Hanne and Christophersen, Ingrid E and Tveit, Arnljot and Berge, Trygve},
title = {Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study},
journal = {European Heart Journal},
year = {2024},
doi = {10.1093/eurheartj/ehad659}
}
EUVIMED